Login

Epinastine-13C,d3 (hydrobromide)

CAT:
804-HY-B0640S-02
Size:
5 mg
Price:
Ask
For price, please contact [email protected]
  • Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
  • Dry Ice Shipment: No
Epinastine-13C,d3 (hydrobromide) - image 1

Epinastine-13C,d3 (hydrobromide)

  • UNSPSC Description: Epinastine-13C,d3 (hydrobromide) is the 13C- and deuterium labeled Epinastine. Epinastine (WAL801) is an antihistamine and mast cell stabilizer. Epinastine is a potent, selective and orally-active histamine H1 receptor antagonist. Epinastine also inhibits IL-8 release and has an antiallergic action[1][2][3][4].
  • Target Antigen: Histamine Receptor; Isotope-Labeled Compounds
  • Type: Isotope-Labeled Compounds
  • Related Pathways: GPCR/G Protein;Immunology/Inflammation;Neuronal Signaling;Others
  • Applications: Metabolism-protein/nucleotide metabolism
  • Field of Research: Inflammation/Immunology; Endocrinology
  • Solubility: 10 mM in DMSO
  • Smiles: NC1=N[13C]([2H])([2H])C2([2H])N1C3=CC=CC=C3CC4=CC=CC=C24.[H]Br
  • Molecular Weight: 334.23
  • References & Citations: [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-223.|[2]Fugner, A., et al., In vitro and in vivo studies of the non-sedating antihistamine epinastine. Arzneimittelforschung, 1988. 38(10): p. 1446-53.|[3]Kamei, C., et al., Antiallergic effect of epinastine (WAL 801 CL) on immediate hypersensitivity reactions: (I). Elucidation of the mechanism for histamine release inhibition. Immunopharmacol Immunotoxicol, 1992. 14(1-2): p. 191-205.|[4]Kohyama, T., et al., A novel antiallergic drug epinastine inhibits IL-8 release from human eosinophils. Biochem Biophys Res Commun, 1997. 230(1): p. 125-8.|[5]Roeder, T., J. Degen, and M. Gewecke, Epinastine, a highly specific antagonist of insect neuronal octopamine receptors. Eur J Pharmacol, 1998. 349(2-3): p. 171-7.
  • Shipping Conditions: Room temperature
  • Clinical Information: No Development Reported